English

Annual Report for the fiscal year 2023

Report this content

Copenhagen, Denmark, 22 February 2024 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) hereby publishes the Annual Report for the fiscal year of 2023. The Annual Report is available as an attached file to this release and on the Company’s website. Below is a summary of the report.

"2023 was a busy year for Curasight where we made significant progress on our mission to revolutionize cancer care. Our theranostics approach for improved diagnosis and treatment options for certain cancers was supported by the announcement of preclinical data using our therapeutic platform uTREAT® in both non-small cell lung cancer and brain cancer, and positive clinical data from our phase II study using uTRACE® in primarty brain cancer. Additionally, we signed an important partnership with Curium Inc., a global leader in radiopharmaceuticals, for the development and commercialisation of uTRACE® in prostate cancer and were pleased to have shown progress in this partnership early this year, with the announcement that we had reached the first milestone under the deal.” Commented Curasight’s CEO Ulrich Krasilnikoff. “We look forward to continuing momentum in 2024, in particular with our updated strategy to accelerate clinical development in parallel of both our therapeutic (uTREAT®) and diagnostic (uTRACE®) platforms by conducting a phase I/IIa basket study with five different cancers, funded in part by the proceeds form the rights issue that we recently launched.”

Financial Highlights January – December 2023

  • Gross loss amounted to kDKK -25,729 (kDKK -11,488)
  • Operating loss amounted to kDKK -33,214 (kDKK -18,862)
  • Loss before tax amounted to kDKK -33,220 (kDKK -19,488)
  • Loss for the year amounted to kDKK -26,169 (kDKK -18,349)
  • Total assets amounted to kDKK 38,742 (kDKK 59,667)
  • Equity ratio amounted to 81,0% (96,5%)
  • Earnings per share amounted to DKK -1,32 (DKK -0,92)

Numbers in parenthesis are numbers from the same period in 2022.

Business Highlights from 2023

February 23, Curasight published the Annual Report 2022 and Year-End Report Q4 2022.

March 15, Curasight held an Annual General Meeting. Resolutions with summarized decisions are available on the company’s website.

May 1, Curasight announced that it has entered into an exclusive global license and collaboration agreement with Curium Inc. – a global leader in radiopharmaceuticals – for the development and commercialization of uTRACE® for use in prostate cancer.

  • Curasight to develop its proprietary uTRACE® PET imaging technology to obtain regulatory approval in EU and USA, with Curium responsible for manufacturing and commercialization.
  • Curasight eligible for up to USD 70 million in development and commercial milestones as well as double-digit royalties on sales on eventual commercialization.
  • The agreement supports Curasight’s strategy to leverage partnerships as it progresses its uPAR theranostic solution to diagnose and treat certain types of cancer.

June 7, Curasight announced preclinical data demonstrating the effectiveness of uTREAT® in treating aggressive brain cancer (glioblastoma). The results from the study validate Curasight’s strategic focus on developing uTREAT® as a viable treatment option for patients with aggressive brain cancer.

June 29, Curasight announced positive results from the investigator-initiated phase II study using uPAR-PET (uTRACE®) in primary brain cancer. The study found that uPAR-PET/MR was a suitable target for the detection and prognosis of primary glioblastomas, the most common type of primary brain cancer.

June 29, Curasight announced positive results from the investigator initiated phase II study using uPAR-PET (uTRACE®) in primary brain cancer. The study found that uPAR-PET/MR was a suitable target for the detection and prognosis of primary glioblastomas, the most common type of primary brain cancer.

October 18, Curasight announced positive preclinical data demonstrating preclinical proof of concept of uTREAT® in treating non-small cell lung cancer (NSCLC), which follows the announcement earlier this year of positive preclinical results of uTREAT® in glioblastoma.

December 13, Curasight announced that they signed an agreement with ABX-CRO, an experienced international clinical research organization serving the pharmaceutical industry, to run the phase 2 study investigating uTRACE® in improving the diagnosis of prostate cancer.

December 18, Curasight announced the submission of clinical trial application (CTA) to the European Medicines Agency (EMA) for the investigation of uTRACE® in a phase 2 trial as a non-invasive alternative or supplement to traditional biopsies in prostate cancer patients in active surveillance.

For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO

Phone: +45 22 83 01 60

E-mail: uk@curasight.com www.curasight.com

Curasight is a clinical development company based in Copenhagen, Denmark. The Company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging (uTRACE®) and Radioligand Therapy (uTREAT®) Theranostic Platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology is expected to improve diagnosis and provide more gentle and efficient treatment of multiple cancer types.

Subscribe

Documents & Links